{"entity":{"id":"waveline-003","kind":"trial","name":"waveLINE-003","aka":[],"tldr":"waveLINE-003 tests a ROR1-directed ADC added to standard salvage chemotherapy.","summary":"waveLINE-003, trial NCT05139017 sponsored by Merck, is a phase 2/3 trial testing the ROR1-directed antibody-drug conjugate zilovertamab vedotin, also known as MK-2140, added to rituximab, gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma after at least one line, in transplant-ineligible or post-transplant patients. A companion frontline trial, waveLINE-010, tests the drug with R-CHP. OnCo links it to lymphoma, ROR1 as a target and zilovertamab vedotin. It is recruiting with no results, and whether ROR1, a target without an approved drug, can be exploited safely with an ADC is the question it exists to answer.","status":"recruiting","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT05139017","url":"https://clinicaltrials.gov/study/NCT05139017"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["adc"],"targets":["ror1"],"drugs":["zilovertamab-vedotin"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05139017","phase":"2/3","setting":"R/R DLBCL after ≥1 line: zilovertamab vedotin + R-GemOx vs R-GemOx","sponsor":"Merck","participation":[{"nct":"NCT05139017","source":"https://clinicaltrials.gov/study/NCT05139017","fetchedAt":"2026-10-07T16:53:34.728Z","studySha256":"7fe6eefda11799cdb2592b1b81eedc03e7f220d3d99002ec0bc6cf03c2278bb1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":290,"enrolmentType":"ESTIMATED","siteCount":135,"recruitingSiteCount":50,"countries":["Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Costa Rica","Denmark","France","Greece","Guatemala","Hong Kong","Israel","Italy","Japan","Mexico","New Zealand","Peru","Poland","South Korea","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","United States"]}],"started":"2022-01-14","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/waveline-003/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/"}],"drug":[{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}